Takara Bio and Eppendorf cooperate

Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency

29-Aug-2023 - Takara Bio Inc. (Takara Bio) and Eppendorf SE, two renowned leaders in the life science industry, are pleased to announce their collaboration through a strategic co-marketing agreement. This partnership aims at jointly developing cutting-edge solutions to automate Takara Bio’s chemistries on ...

Takara Bio Europe Goes Direct in 2012

Clontech owner demonstrates confidence in European research market by establishing wholly-owned sales organisation

02-Feb-2012 - Takara Bio Europe announced that it will start selling its range of Takara brand products exclusively and directly to customers in the UK, Germany, Austria and Switzerland, with immediate effect. The decision means customers will be able to buy both Takara and Clontech brand products from one ...

MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

30-Nov-2010 - MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc.. Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation ...

Clontech Laboratories & TET Systems Announce the Broadening of Their License Agreement

28-Jul-2010 - Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights ...

Takara Bio to Acquire Clontech Unit of BD Biosciences

05-Jul-2005 - Takara Bio Inc. announced that it has entered into a definitive agreement to acquire the Clontech unit ("Clontech") of BD Biosciences, mainly consisting of Clontech Laboratories Inc. (employees: 190), for USD $60 million (adjusted from USD $65 million due to the retention of certain inventories ...

Takara Bio: Clinical Development of "Cancer Immunotherapy" jointly performed with CI&H, Chinese Academy of Medical Sciences

17-Sep-2004 - Takara Bio Inc. agreed on August 31, 2004 to undertake clinical development of cancer immunotherapy intended for commercialization jointly with Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing. Presently, in China, too, malignant tumor is the leading cause of death, ...